Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00107445 | EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00050414 | A Study of Trabectedin in Patients With Advanced Ovarian Cancer | completed | Phase 2 | 147 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Jan 10, 2013 |
| clinicaltrials |
| NCT00396591 | AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites | completed | Phase 2 | 16 | SanofiINDUSTRY | 3 | Jan 10, 2013 | clinicaltrials |
| NCT00063895 | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00050440 | Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma | completed | Phase 2 | 50 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 4 | Jan 8, 2013 | clinicaltrials |
| NCT00003896 | S9912 Combination Chemo in Stage III Ovarian Cancer, | completed | Phase 2 | 68 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 4, 2013 | clinicaltrials |
| NCT00327444 | Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites | completed | Phase 2 / Phase 3 | 58 | SanofiINDUSTRY | 9 | Jan 1, 2013 | clinicaltrials |
| NCT00881140 | Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids | completed | Phase 2 | 30 | BioPro Medical LtdINDUSTRY | 1 | Dec 19, 2012 | clinicaltrials |
| NCT00610714 | AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer(OVERT-1) | completed | Phase 2 | 211 | AstraZenecaINDUSTRY | 12 | Dec 18, 2012 | clinicaltrials |
| NCT00181688 | Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer | completed | Phase 2 | 35 | Massachusetts General HospitalOTHER | 1 | Dec 5, 2012 | clinicaltrials |
| NCT00837161 | Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids | completed | Phase 1 / Phase 2 | 11 | Philips HealthcareINDUSTRY | 1 | Dec 4, 2012 | clinicaltrials |
| NCT00316173 | Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer | completed | Phase 2 | 77 | GlaxoSmithKlineINDUSTRY | 2 | Nov 27, 2012 | clinicaltrials |
| NCT00840450 | Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin | terminated | Phase 2 | 14 | NYU Langone HealthOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT01724944 | LYmphadenectomy After NeoAdjuvant Chemotherapy(LYANA) | unknown | Phase 1 / Phase 2 | 65 | Catholic University of the Sacred HeartOTHER | 1 | Nov 12, 2012 | clinicaltrials |
| NCT00002671 | Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Nov 9, 2012 | clinicaltrials |
| NCT00005051 | Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Nov 9, 2012 | clinicaltrials |
| NCT00861120 | Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type(PaLiDo) | completed | Phase 2 | 33 | Vejle HospitalOTHER | 4 | Oct 26, 2012 | clinicaltrials |
| NCT00078845 | Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2012 | clinicaltrials |
| NCT00069160 | Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Oct 12, 2012 | clinicaltrials |
| NCT01012336 | Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin | completed | Phase 2 | 89 | Samsung Medical CenterOTHER | 1 | Oct 10, 2012 | clinicaltrials |
| NCT00563836 | Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer | completed | Phase 2 | 41 | Neovii BiotechINDUSTRY | 2 | Oct 3, 2012 | clinicaltrials |
| NCT00005612 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer(ETC) | terminated | Phase 1 / Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 26, 2012 | clinicaltrials |
| NCT00003939 | Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma | completed | Phase 2 | 132 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Sep 24, 2012 | clinicaltrials |
| NCT00006230 | Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer | completed | Phase 2 | 51 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Sep 24, 2012 | clinicaltrials |
| NCT00006357 | STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 91 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Sep 24, 2012 | clinicaltrials |
| NCT00014599 | Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva | completed | Phase 2 | 31 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Sep 24, 2012 | clinicaltrials |
| NCT00022620 | Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer | completed | Phase 2 | — | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Sep 24, 2012 | clinicaltrials |
| NCT00052312 | Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer | completed | Phase 2 | 141 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Sep 24, 2012 | clinicaltrials |
| NCT00003072 | Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer | completed | Phase 2 | 80 | University of California, San FranciscoOTHER | 1 | Sep 21, 2012 | clinicaltrials |
| NCT00392769 | Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer | completed | Phase 2 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 6, 2012 | clinicaltrials |
| NCT00296816 | TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary(TEACO) | completed | Phase 2 | 132 | SanofiINDUSTRY | 1 | Aug 23, 2012 | clinicaltrials |
| NCT00516841 | A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer | terminated | Phase 2 | 16 | Facet BiotechINDUSTRY | 2 | Aug 23, 2012 | clinicaltrials |
| NCT01661868 | Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 21, 2012 | clinicaltrials |
| NCT00004081 | Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 30 | Beth Israel Deaconess Medical CenterOTHER | 1 | Aug 13, 2012 | clinicaltrials |
| NCT00501644 | Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00085384 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | terminated | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00334295 | Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. | completed | Phase 2 | 35 | AstraZenecaINDUSTRY | 1 | Jul 31, 2012 | clinicaltrials |
| NCT00505739 | Mifepristone for Patients With Endometrial Cancer and LGESS | completed | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2012 | clinicaltrials |
| NCT00377429 | Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy | completed | Phase 2 | 47 | Neovii BiotechINDUSTRY | 1 | Jul 19, 2012 | clinicaltrials |
| NCT00267488 | Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer | completed | Phase 2 | 70 | GlaxoSmithKlineINDUSTRY | 3 | Jul 11, 2012 | clinicaltrials |
| NCT00002903 | Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer | completed | Phase 2 | 25 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 14 | Jul 2, 2012 | clinicaltrials |
| NCT00002916 | Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer | completed | Phase 2 | 44 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Jul 2, 2012 | clinicaltrials |
| NCT00281515 | Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer | completed | Phase 2 | 105 | AGO Study GroupOTHER | 1 | Jun 29, 2012 | clinicaltrials |
| NCT00445549 | Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 26, 2012 | clinicaltrials |
| NCT01290406 | BEZ235 Trial in Patients With Advanced Endometrial Carcinoma | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 21, 2012 | clinicaltrials |
| NCT00003127 | S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer | completed | Phase 2 | 57 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 14, 2012 | clinicaltrials |
| NCT00003369 | S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer | completed | Phase 2 | 56 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 14, 2012 | clinicaltrials |
| NCT00006262 | Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer | terminated | Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 11, 2012 | clinicaltrials |
| NCT00003669 | Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Jun 7, 2012 | clinicaltrials |
| NCT00003670 | Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Jun 7, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jan 16, 2013source: clinicaltrials